A detailed history of Geode Capital Management, LLC transactions in Merus N.V. stock. As of the latest transaction made, Geode Capital Management, LLC holds 52,096 shares of MRUS stock, worth $2.59 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
52,096
Previous 52,186 0.17%
Holding current value
$2.59 Million
Previous $3.09 Million 15.71%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$47.19 - $58.84 $4,247 - $5,295
-90 Reduced 0.17%
52,096 $2.6 Million
Q2 2024

Aug 09, 2024

SELL
$39.81 - $60.2 $209,878 - $317,374
-5,272 Reduced 9.18%
52,186 $3.09 Million
Q1 2024

May 13, 2024

BUY
$28.03 - $51.82 $107,915 - $199,507
3,850 Added 7.18%
57,458 $2.59 Million
Q4 2023

Feb 13, 2024

BUY
$20.06 - $28.66 $3,009 - $4,299
150 Added 0.28%
53,608 $1.47 Million
Q3 2023

Nov 13, 2023

BUY
$20.13 - $27.29 $444,611 - $602,754
22,087 Added 70.41%
53,458 $1.26 Million
Q2 2023

Aug 11, 2023

BUY
$18.33 - $27.18 $120,996 - $179,415
6,601 Added 26.65%
31,371 $825,000
Q3 2022

Nov 14, 2022

BUY
$18.64 - $28.93 $68,222 - $105,883
3,660 Added 17.34%
24,770 $496,000
Q1 2022

May 13, 2022

BUY
$23.58 - $30.91 $14,761 - $19,349
626 Added 3.06%
21,110 $558,000
Q2 2021

Aug 13, 2021

BUY
$20.0 - $25.48 $109,040 - $138,916
5,452 Added 36.27%
20,484 $431,000
Q1 2021

May 12, 2021

BUY
$16.14 - $29.11 $50,243 - $90,619
3,113 Added 26.12%
15,032 $314,000
Q4 2020

Feb 12, 2021

SELL
$11.4 - $18.36 $51,573 - $83,060
-4,524 Reduced 27.51%
11,919 $208,000
Q2 2019

Aug 14, 2019

BUY
$12.93 - $16.83 $18,826 - $24,504
1,456 Added 9.72%
16,443 $240,000
Q4 2018

Feb 13, 2019

BUY
$11.46 - $20.81 $27,194 - $49,382
2,373 Added 18.81%
14,987 $209,000
Q2 2018

Aug 14, 2018

BUY
$16.77 - $22.76 $211,536 - $287,094
12,614 New
12,614 $287,000

Others Institutions Holding MRUS

About Merus N.V.


  • Ticker MRUS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,878,200
  • Market Cap $2.28B
  • Description
  • Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase...
More about MRUS
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.